drugset / Trial / NCT00674258

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

NCT00674258

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and time to progression of HLA-A\*2402 restricted epitope peptides URLC10, TTK and KOC1 emulsified with Montanide ISA 51.

Timeline

Start
2008-05
Primary completion
2009-04
Completion
2009-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject KOC1 Vaccine 1 mg Subcutaneous
Subject TTK Vaccine 1 mg Subcutaneous
Subject URLC10-117 Peptide 1 mg Subcutaneous